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targeted in this analysis. ConClusions: Prospective inclusion of health-economic 
endpoints in clinical trials for PAD is important to support future decision-making 
by payers and providers. The OPTIMIZE study collects targeted information on qual-
ity of life and resource utilization to facilitate future health-economic analyses.
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objeCtives: Dexmedetomidine was approved for ICU sedation in adults in the 
EU in 2011, but has been available in other countries since 1999 and used in many 
different clinical situations including in children. This study evaluated off-label 
use of dexmedetomidine in usual care in the EU. Methods: A chart review DUS 
of patients treated with dexmedetomidine was conducted in 16 hospitals across 
Austria, Finland, Germany and Poland. Patients were identified either prospectively 
or retrospectively, with anonymised data abstraction performed retrospectively 
post-administration. Chart data on patient demographics, indication, dexmedetomi-
dine administration, concomitant medications and therapeutic effectiveness were 
collected via an electronic data collection tool. Results: 2,000 patients received 
2,159 administrations of which 36.6% contained elements not according to the 
SmPC. Collecting off-label use was a concern to some sites and ethics committees, 
resulting in high site attrition and relatively slow start-up. Collecting sufficient 
mature dexmedetomidine use early after launch required focus on prolific users, 
while excluding regions where dexmedetomidine uptake was slow. Site selection 
was performed blinded by the Steering Committee to avoid bias. The study required 
collaboration across many hospital departments. Varied medical records systems 
required site-specific approaches to patient identification; some sites performing 
database searches, others using a manual process. Restricted access to records of 
patients from other hospital departments in some cases necessitated completion of 
paper worksheets by non-study hospital staff. Anonymised data collection avoided 
the need for informed consent but precluded patient verification and data queries, 
thus robust electronic data checks were essential. Data were regularly reviewed 
for evidence of duplication of patients within sites. ConClusions: Chart review 
DUS was successful in investigating off-label dexmedetomidine prescribing. Study 
conduct flexibility was essential to meet different needs of study sites and ensure 
study success. Close attention to potential sources of bias was required to ensure 
a robust outcome.
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objeCtives: The choice of comparator drug is a critical factor in successful mar-
ket access, pricing and reimbursement by national payer bodies. Varying require-
ments specified for the comparator selected have led to approaches that differ by 
country. Legislation introduced in Germany in particular has affected studies in 
progress. As HTA agencies differ per country, the objective of the analysis which 
covers Germany, UK and France is twofold: - Do market access regulations influ-
ence trial design? - Do the chosen trial designs cover national pricing and reim-
bursement regulations? Methods: Published benefit assessments from selected 
HTA agencies websites such as G-BA, NICE and HAS were used to analyze diabetes 
drug assessments in terms of requested comparators and final recommendation. 
Furthermore, Clincialtrials.gov was used to analyze the trials in diabetes and their 
design. Results: Of the 49 HTA assessments by G-BA, HAS and NICE analyzed, 
10 assessments (20%) had an inappropriate comparator chosen. This resulted in 
eight negative recommendations, one positive with restrictions and one positive 
recommendation. Most of the HTA assessments with a positive outcome presented 
head-to-head or adjusted indirect comparisons. Unadjusted indirect comparisons 
were mainly rejected; and a mixed approach was allowed in France and England but 
not recommended in Germany. ConClusions: Having solely marketing authoriza-
tion (EMA) in mind when designing a trial can lead to an unsuccessful drug launch 
with regards to national pricing and reimbursement decisions. More specifically, 
the choice of comparator is considered as the most important factor for benefit 
assessment in Germany and the methodology applied is crucial to obtaining a posi-
tive outcome. In France and England, the use of specific guidelines for the choice 
of comparators and comparison methodology developed by NICE and validated by 
the HAS, is particularly relevant to obtain a positive outcome.
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objeCtives: Management of symptomatic diabetic peripheral neuropathy (DPN) 
is complicated by a lack of evidence regarding the comparative effectiveness of 
available agents, frequent side effects, and the need for ongoing symptom assess-
objeCtives: To compare trials of the four anti-epileptic drugs (AEDs) approved 
specifically for the adjunctive treatment of primary generalized tonic-clonic sei-
zures (PGTCS): topiramate [TPM] (1999), lamotrigine [LTG] (2006), levetiracetam [LEV] 
(2007), lamotrigine-XR [LTG-XR] (2010), and perampanel [PER] (2015). Methods: 
Trial data were identified through a systematic literature review. Main inclusion 
criteria: randomized, controlled, PGTCS with or without other generalized seizure 
types, and published 1989-2014. Key exclusion criteria: predominantly children/
adolescents and intravenous drug study. Data were abstracted from indexed pub-
lications, clinicaltrials.gov, and regulatory reports of the United States Food and 
Drug Administration and European Medicines Agency. Results: Five PGTCS trials 
[TPM-RCT (n= 80), LTG-RCT (n= 117), LEV-RCT (n= 164), LTG-XR-RCT (n= 146), PER-RCT 
(n= 163)] were identified. All trials were placebo-controlled where baseline AEDs 
were continued into the trial and consisted of the standard of care (SOC) at the time. 
Trial designs were similar with minor exceptions: PER-RCT allowed 1-3 baseline 
AEDs (others 1-2), LEV-RCT and PER-RCT had shorter titration periods (4 versus 7 & 8 
weeks), and LEV-RCT had the longest maintenance period (20 versus 12 & 13 weeks). 
Baseline PGTCS frequency was similar between trials except TPM-RCT which was 
higher (4.5-5.0 versus 2.3-3.0 per 28 days). The presence of LTG, LEV, and zonisamide 
in the SOC increased over time while the use of carbamazepine, phenytoin, and 
phenobarbital decreased. Valproate and TPM use fluctuated but appeared stable. In 
the latest phase III trial, PER-RCT had the following SOC composition, 43% valproate, 
39% LTG, 15% TPM, 31% LEV, 12% zonisamide, 8% carbamazepine, 6% phenytoin, and 
4% phenobarbital. ConClusions: Our review indicates that while the trial designs 
have remained similar over time, the SOC has evolved with the approval of new 
PGTCS medications. The latest trial, PER-RCT, has an SOC that is comprised heavily 
of the most recently approved PGTCS drugs.
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objeCtives: Guidance and standards are made available by the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) as refer-
ence tools for methodology and transparency of post-authorization studies. They 
are cited by the Guideline on good pharmacovigilance practices (GVP) Module 
VIII as relevant scientific guidances. Here we report an analysis conducted on 
Pharmacovigilance Risk Assessment Committee (PRAC) minutes regarding meth-
odological issues. Methods: All publicly available minutes of PRAC meetings from 
July 2012 to March 2015 were considered. The number of submitted post-authoriza-
tion safety study (PASS) protocols requiring endorsement was recorded (excluding 
advices), as well as endorsement/ refusal and reason. ENCePP documentation was 
consulted. Results: From July 2012 to March 2015, 33 PASS protocols submitted to 
PRAC requiring endorsement were considered, increasing with years: 2 in 2012, 8 
(17 considering resubmissions) in 2013, 18 (24 considering resubmissions) in 2014. 
The total number of evaluations was 54. Thirteen were endorsed at the first step 
(including endorsement with changes requested), while 20 required at least one 
amendment reaching approval up to 15 months after submission. The most com-
mon reasons for refusal concerned study design (20 cases), mainly reporting designs 
not allowing to fulfil study objectives (N= 14). Furthermore, PRAC review asked for 
alternatives to reduce bias and confounding (N= 2), simplifications aiming at rein-
forcing the observational nature of the study (N= 1), further justification of sample 
size (N= 1) and considerations on feasibility (N= 1). From 2013 to 2014 an increasing 
number of endorsed PASS protocols was observed (7/17 and 12/24 respectively). 
During the same years ENCePP Checklist for Study Protocols and ENCePP Guide 
on Methodological Standards in Pharmacoepidemiology were reviewed, and the 
number of studies included in the ENCePP e-register increased. ConClusions: 
An increasing use of guidance and standards will allow strengthening robustness 
of design and results of observational studies.
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objeCtives: Present the economic study design of the OPTIMIZE study on orbital 
atherectomy system (OAS) and drug-coated balloon (DCB) treatment of peripheral 
artery disease (PAD) patients. Treating patients with calcified peripheral arterial 
lesions can be challenging and costly. The impact of OAS and DCBs in treating calci-
fied lesions has been studied independently. The objective of this study design is to 
assess the economic impact of treating below-the-knee (BTK) calcified PAD lesions 
with OAS+DCB compared to treating BTK calcified lesions with DCB alone (without 
OAS). Methods: This prospective, multi-center, post-market pilot study comparing 
OAS with adjunctive DCB angioplasty versus DCB angioplasty alone for treatment 
of calcified BTK lesions is a 1:1 randomized controlled study of 50 patients with 
calcification. In addition to clinical outcomes, health economic outcomes will be 
collected for the index procedure as well as additional procedures required during 
the clinical follow-up period. Results: Health economic outcomes will be meas-
ured at the index procedure, at 30 days, 3 months, 6 months, 12 months, and 24 
months post procedure for the treatment of PAD and its complications (repeat 
procedures, amputations, etc.). Health-related quality of life will be measured using 
the EQ-5D instrument. Resource utilization will be collected from case report forms 
and hospital accounting systems, using site-specific procedure code information 
of relevant OPS (German sites), CHOP (Swiss sites), and MEL codes (Austrian sites). 
Analyses from the third-party payer perspective will be informed by country-specific 
reimbursement amounts, using Germany as the initial reference case. Resulting cost 
difference and incremental cost-effectiveness are the main economic outcomes 
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varied, this study aimed to review the characteristics of ongoing studies of incentive-
based interventions. Methods: A targeted search was conducted in ClinicalTrials.
gov using the search terms “incentive”, “reward”, “contingency”, “contingency man-
agement”, “prize”, “reinforcement”, “token”, “voucher”, “conditional cash transfer”, 
“CCT, “pay for performance” or “P4P”. Studies were selected for inclusion if they 
investigated the use of ≥ 1 incentive in modifying health-related behaviour, had 
the status “active, not recruiting,” and the effect of incentives was distinguishable 
between study arms. Results: Of the 204 search results, 42 met the inclusion cri-
teria. The majority of these studies (n= 29) took place in North America, and almost 
half (n= 20) investigated the use of a financial reward or voucher as the incentive. The 
rationale for the use of an incentive was most commonly the promotion of healthy 
lifestyle choices relating to diet and physical activity (n= 17), whilst other studies 
targeted behaviours such as medication/treatment adherence (n= 9) or breaking 
addiction (n= 8). The use of incentives in the management of chronic conditions 
or diseases such as hypertension, diabetes or HIV was investigated in 11 of the 
included studies. ConClusions: These initial results show that ongoing studies 
of incentives predominantly investigate the promotion of healthy lifestyle choices, 
with financial rewards or vouchers being the most common form of incentive. This 
emphasis on promoting healthy lifestyle choices may reflect the difficulties that 
individuals otherwise have in achieving these complex behavioural changes, and 
perhaps the importance of these changes to healthcare systems worldwide. Studies 
which assess the use of inventive-based interventions for modifying health-related 
behaviours, or compare the effectiveness of different incentives in improving out-
comes, warrant further investigation.
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objeCtives: A core outcome set (COS) is a standardised set of outcomes which should 
be measured and reported, as a minimum, in all effectiveness trials for a specific 
health area. A systematic review of COS identified 198 COS [1]. A range of methods 
were used, and furthermore, 164/178 studies that described the methods used did not 
provide an explanation regarding their choice of methodology. There is little guidance 
about how to conduct or report COS studies and it is currently uncertain which of 
these methods are the most suitable, feasible and efficient. It is important to inves-
tigate COS developers’ choice of approach as this is a new area of research, and in 
order to formulate guidance in this area we need to try and understand the current 
situation, including the influences of methodological choices being made. Methods: 
We have used a mixed methods approach, using qualitative methods (semi-structured 
interviews) and a web-based survey. Results: Interviews are currently underway. 
The survey was sent out to 169 COS developers, with 81/169 responses. Methodological 
decisions were based most commonly on previous work, expert advice or own expe-
rience. Challenges of this work included resources (time, funding and technology), 
achieving consensus, a lack of data and challenges with involving patients in the 
process. ConClusions: In order to develop methodological guidance for COS devel-
opment we need to try to understand what factors have informed the ways in which 
researchers have developed COS. This is the first insight into COS developers’ choice 
of methodology and their experiences of the process. These results will provide a more 
comprehensive account of COS development, ultimately facilitating the formulation 
of guidance in this area. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke 
M, Williamson PR: choosing important health outcomes for comparative effectiveness 
research: a systematic review. PLoS ONE 2014,9:e99111.
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objeCtives: The growing market for personal wellness technology has increased 
the awareness of the potential role of sleep and activity measures in clinical trials. 
However there is significant debate around the clinical value of these endpoints, 
position of the devices and duration of the recording period. 90 Industry Sponsored 
Trials were identified from a comprehensive review of Clinical Trials.gov, EU Clinical 
Trials Register and The International Standard Randomised Controlled Trial Number 
register (ISRCTN) as having used Actigraphy (activity and sleep) derived outcome 
measures. This retrospective analysis is designed to establish if there is commonality 
among the existing Actigraphy endpoints and study design that can provide a frame-
work for future clinical trials. Methods: Systematic review of the subset of industry 
sponsored trials which had been filtered using the word “Actigraphy” and the brand 
names of the best known devices. These trials were then subdivided by therapeutic 
areas and analysed for outcome measures and study design. Results: Therapeutic 
Areas (CNS, Dermatology, Respiratory, Cardiovascular, Diabetes, Oncology), Discrete 
and Common Endpoints: Sleep (47%), Activity (23%), PLM (12%). Wear time: when 
stated varied from 10 hours to 4 weeks. ConClusions: The preponderance of the 
trials reviewed were in the CNS therapeutic area (73%). Actigraphy derived endpoints 
were used both as primary and secondary outcome measures. Sleep endpoints were 
the most common outcome measures, however there was considerable variability 
regarding the sleep parameter selected, the terminology used in the protocols and the 
wear time. In order for the value of Actigraphy derived endpoints to be maximised and 
universally adopted, the choice of endpoint and study design need to be standardized.
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ment and treatment titration for maximal clinical benefit. In this paper, we pre-
sent the rationale for and implementation challenges of the Diabetes Telephone 
Study (DTS), a randomized trial designed to improve quality of life among newly 
treated DPN patients. Methods: This pragmatic cluster randomized controlled 
trial tests whether collecting and feeding back real-time patient-reported data 
about experiences with newly prescribed DPN medicines can improve treatment 
outcomes. Randomization occurred at the physician level and patients are pro-
spectively identified as they receive a new DPN-related prescription (October 2014 
- November 2015). Patients in the intervention group report on medication taking 
behavior, symptoms, side effects, self-titration and satisfaction with treatment 
during three interactive automated calls during the six months following a new 
prescription. This information is entered into the electronic medical record and, 
among patients experiencing problems (e.g., side effects), flagged for immediate 
physician follow-up. We compare outcomes (quality of life, medication changes, 
patient-physician communication) for the intervention group to those in a control 
group who receive similarly timed non-interactive automated calls consisting of 
diabetes educational messages. Results: We designed this study to minimize com-
mon threats to internal validity, including ascertainment bias and contamination. 
However, stakeholder engagement has been critical for tailoring the intervention to 
address pragmatic concerns such as provider time constraints and patient charac-
teristics. ConClusions: Innovative strategies are needed to guide improvements 
in health care delivery for patients with symptomatic DPN. If successful, this inter-
vention provides a critical information feedback loop that would optimize DPN 
medication titration through widely available interactive voice response technology.
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objeCtives: The number of patients posting on health-related social media (SM) sites 
about their experiences is increasing exponentially. There have been well-publicised 
cases where trial participants blog and discuss all kinds of details about the clinical 
trials (CTs) in which they are participating. There has been expression of concern 
that this could compromise the integrity of CTs. The primary objective of this study 
was to explore how frequently CTs were discussed in selected patient SM sites and 
to characterise the types of discussions taking place and how they might impact on 
clinical trials. Methods: Diabetes and breast cancer were selected as the target 
conditions as these have a large number of clinical trials and patient-related SM 
discussions with high participation levels. Over one million postings identified from 
the largest United States and United Kingdom-based SM sites were evaluated for 
content relating to discussion of CTs Results: Over 1 million posts were reviewed 
with 0.9% of posts mentioning clinical trials. The average number of views of post-
ings mentioning CTs were 1,025 which was just lower than the average of 1,147 for all 
posts. Discussions of active CTs by participants were rare. There were no discussions 
in the sample that risked un-blinding of CTs. There were equally discussion encour-
aging and discouraging clinical trials. Overall there were 37 threads which debated 
whether to join clinincal trials or not. Two patient SM sites had recently added CT 
specific forums. ConClusions: Use of SM by clinical trial participants is growing, 
and there is a potential for both harm and benefit in these discussions and in their 
visibility through a browser. Trial participants should undergo some basic training on 
the risks of SM discussion and those running CTs may need to consider the potential 
impact of social media on the trial and consider periodic monitoring of SM content.
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objeCtives: The questionnaire of the Cochrane Collaboration developed to assess 
risks of six key systematic biases in randomized controlled trials (RCT) is needed 
for wide use in Russia, so it was translated into Russian and validated. Methods: 
Two experts (F.V.K. and K.G.R.) with 4-year experience of evidence assessment used 
the Russian version of the questionnaire to consider biases in 20 RCT published in 
2002-2012. The inter-rater agreement was estimated using Kappa (K) coefficient, it 
was calculated for six key domains and also for overall summarizing risk of bias (low, 
high, unclear) within a study (across domains). Results: Two experts demonstrated 
good, very good and excellent agreement on each key domain and also good overall 
summarizing agreement (K= 0.767, 95% CI 0.527; 1.000). We propose to consider the 
conflict of interests not as additional but as obligatory (the 7th) key domain (the 
agreement in this domain is very good, K= 0.840, 95% CI 0.641; 1.000). As it appeared 
to influence greatly the overall estimation summarizing risk we also propose to 
modify slightly the Cochrane rule of summary assessment of the risk of bias (across 
domains). The modified rule allows unclear risk of bias in one key domain to have 
low overall summarizing risk. The final version of the document also provides good 
agreement (K= 0.785, 95% CI 0.503; 1.000). ConClusions: The Russian version of 
the Cochrane questionnaire is ready to use also as a web-based tool.
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objeCtives: Incentive-based interventions aim to improve health outcomes by 
rewarding individuals for specific health-related behaviours such as exercise, medi-
cation adherence or smoking cessation. Since the types and targets of incentives are 
